{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:25:03Z","timestamp":1792013103150,"version":"4.4.0"},"reference-count":27,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2014,4,22]],"date-time":"2014-04-22T00:00:00Z","timestamp":1398124800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2014,4,22]],"date-time":"2014-04-22T00:00:00Z","timestamp":1398124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"crossref","award":["NF01000042"],"award-info":[{"award-number":["NF01000042"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"crossref"}]},{"name":"FDA Orphan Fund Program Grant"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Blood Cancer"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1002\/pbc.25041","type":"journal-article","created":{"date-parts":[[2014,4,22]],"date-time":"2014-04-22T04:27:02Z","timestamp":1398140822000},"page":"1598-1602","source":"Crossref","is-referenced-by-count":92,"title":["Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas"],"prefix":"10.1002","volume":"61","author":[{"given":"Brigitte C.","family":"Widemann","sequence":"first","affiliation":[{"name":"Pediatric Oncology Branch; National Cancer Institute; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dusica","family":"Babovic-Vuksanovic","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics; Mayo College of Medicine; Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Dombi","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch; National Cancer Institute; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela L.","family":"Wolters","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch; National Cancer Institute; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart","family":"Goldman","sequence":"additional","affiliation":[{"name":"Ann and Robert H Lurie Children's Hospital of Chicago; Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staci","family":"Martin","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch; National Cancer Institute; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Goodwin","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch; National Cancer Institute; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Goodspeed","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch; National Cancer Institute; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Kieran","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Children's Hospital Cancer Center; Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Cohen","sequence":"additional","affiliation":[{"name":"Cleveland Clinic; Cleveland Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Blaney","sequence":"additional","affiliation":[{"name":"Texas Children's Hospital; Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"King","sequence":"additional","affiliation":[{"name":"St. Louis Children's Hospital; St. Louis Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Solomon","sequence":"additional","affiliation":[{"name":"Expert Image Analysis LLC; Potomac Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Patronas","sequence":"additional","affiliation":[{"name":"Diagnostic Radiology Department, Clinical Center; National Institutes of Health; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank M.","family":"Balis","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch; National Cancer Institute; Bethesda Maryland"},{"name":"The Children's Hospital of Philadelphia; Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Fox","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch; National Cancer Institute; Bethesda Maryland"},{"name":"The Children's Hospital of Philadelphia; Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth M.","family":"Steinberg","sequence":"additional","affiliation":[{"name":"Biostatistics and Data Management Section; National Cancer Institute; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J","family":"Packer","sequence":"additional","affiliation":[{"name":"Children's National Medical Center; Washington District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,4,22]]},"reference":[{"key":"10.1002\/pbc.25041-BIB0001|pbc25041-cit-0001","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/jmg.2006.045906","article-title":"Guidelines for the diagnosis and management of individuals with neurofibromatosis 1","volume":"44","author":"Ferner","year":"2007","journal-title":"J Med Genet"},{"key":"10.1002\/pbc.25041-BIB0002|pbc25041-cit-0002","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<31::AID-AJMG7>3.0.CO;2-W","article-title":"Plexiform neurofibromas","volume":"89","author":"Korf","year":"1999","journal-title":"Am J Med Genet"},{"key":"10.1002\/pbc.25041-BIB0003|pbc25041-cit-0003","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1212\/01.wnl.0000250332.89420.e6","article-title":"NF1 plexiform neurofibroma growth rate by volumetric MRI: Relationship to age and body weight","volume":"68","author":"Dombi","year":"2007","journal-title":"Neurology"},{"key":"10.1002\/pbc.25041-BIB0004|pbc25041-cit-0004","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1750-1172-7-75","article-title":"Growth dynamics of plexiform neurofibromas: A retrospective cohort study of 201 patients with neurofibromatosis 1","volume":"7","author":"Nguyen","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1002\/pbc.25041-BIB0005|pbc25041-cit-0005","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e3181bd1326","article-title":"Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas","volume":"73","author":"Kim","year":"2009","journal-title":"Neurology"},{"key":"10.1002\/pbc.25041-BIB0006|pbc25041-cit-0006","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jpeds.2011.04.008","article-title":"Plexiform neurofibromas in children with neurofibromatosis type 1: Frequency and associated clinical deficits","volume":"159","author":"Nguyen","year":"2011","journal-title":"J Pediatr"},{"key":"10.1002\/pbc.25041-BIB0007|pbc25041-cit-0007","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jpeds.2011.08.051","article-title":"Pediatric plexiform neurofibromas: Impact on morbidity and mortality in neurofibromatosis type 1","volume":"160","author":"Prada","year":"2012","journal-title":"J Pediatr"},{"key":"10.1002\/pbc.25041-BIB0008|pbc25041-cit-0008","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1517\/13543784.2013.772979","article-title":"Optimizing biologically targeted clinical trials for neurofibromatosis","volume":"22","author":"Gutmann","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1002\/pbc.25041-BIB0009|pbc25041-cit-0009","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/BPO.0b013e31820cad77","article-title":"Resection of plexiform neurofibromas in children with neurofibromatosis type 1","volume":"31","author":"Canavese","year":"2011","journal-title":"J Pediatr Orthop"},{"key":"10.1002\/pbc.25041-BIB0010|pbc25041-cit-0010","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s12307-012-0115-x","article-title":"The plexiform neurofibroma microenvironment","volume":"5","author":"Yang","year":"2012","journal-title":"Cancer Microenviron"},{"key":"10.1002\/pbc.25041-BIB0011|pbc25041-cit-0011","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1006\/bbrc.1994.1118","article-title":"The growth regulation of neurofibroma cells in neurofibromatosis type-1: Increased responses to PDGF-BB and TGF-beta 1","volume":"198","author":"Kadono","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1002\/pbc.25041-BIB0012|pbc25041-cit-0012","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1346-8138.1992.tb03736.x","article-title":"Growth and collagen synthesis of cultured neurofibroma fibroblasts","volume":"19","author":"Sasaki","year":"1992","journal-title":"J Dermatol"},{"key":"10.1002\/pbc.25041-BIB0013|pbc25041-cit-0013","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1183\/09059180.00001111","article-title":"Antifibrotic activities of pirfenidone in animal models","volume":"20","author":"Schaefer","year":"2011","journal-title":"Eur Respir Rev"},{"key":"10.1002\/pbc.25041-BIB0014|pbc25041-cit-0014","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"key":"10.1002\/pbc.25041-BIB0015|pbc25041-cit-0015","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1345\/aph.1R337","article-title":"Pirfenidone: A novel agent for the treatment of idiopathic pulmonary fibrosis","volume":"47","author":"Potts","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1002\/pbc.25041-BIB0016|pbc25041-cit-0016","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1155\/S1110724304308107","article-title":"Survival of human neurofibroma in immunodeficient mice and initial results of therapy with pirfenidone","volume":"2004","author":"Babovic-Vuksanovic","year":"2004","journal-title":"J Biomed Biotechnol"},{"key":"10.1002\/pbc.25041-BIB0017|pbc25041-cit-0017","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1212\/01.wnl.0000243231.12248.67","article-title":"Phase II trial of pirfenidone in adults with neurofibromatosis type 1","volume":"67","author":"Babovic-Vuksanovic","year":"2006","journal-title":"Neurology"},{"key":"10.1002\/pbc.25041-BIB0018|pbc25041-cit-0018","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.pediatrneurol.2007.01.009","article-title":"Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas","volume":"36","author":"Babovic-Vuksanovic","year":"2007","journal-title":"Pediatr Neurol"},{"key":"10.1002\/pbc.25041-BIB0019|pbc25041-cit-0019","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.compmedimag.2004.03.002","article-title":"Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging","volume":"28","author":"Solomon","year":"2004","journal-title":"Comput Med Imaging Graph"},{"key":"10.1002\/pbc.25041-BIB0020|pbc25041-cit-0020","unstructured":"Widemann B Dombi E Gillespie A"},{"key":"10.1002\/pbc.25041-BIB0021|pbc25041-cit-0021","unstructured":"National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, MD, July 13-15, 1987. Neurofibromatosis 1988; 1: 172-178"},{"key":"10.1002\/pbc.25041-BIB0022|pbc25041-cit-0022","volume-title":"Impact of Illness (IPI) Scale parent form: Validity and reliability data for children with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PNs)","author":"Wolters","year":"2010"},{"key":"10.1002\/pbc.25041-BIB0023|pbc25041-cit-0023","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1111\/j.1442-9071.1998.tb01380.x","article-title":"Pirfenidone reduces fibronectin synthesis by cultured human retinal pigment epithelial cells","volume":"26","author":"Zhang","year":"1998","journal-title":"Aust N Z J Ophthalmol"},{"key":"10.1002\/pbc.25041-BIB0024|pbc25041-cit-0024","first-page":"14","article-title":"Preliminary results of a phase II trial of pegylated interferon-alfa-2B (PI) in pediatric patients with documented progression of neurofibromatosis type 1-related unresectable plexiform neurofibromas (PNF)","author":"Jakacki","year":"2012","journal-title":"Neuro-Oncol"},{"key":"10.1002\/pbc.25041-BIB0025|pbc25041-cit-0025","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1148\/radiol.2503080700","article-title":"Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: Determination on whole-body MR images","volume":"250","author":"Cai","year":"2009","journal-title":"Radiology"},{"key":"10.1002\/pbc.25041-BIB0026|pbc25041-cit-0026","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2214\/ajr.180.2.1800419","article-title":"Interobserver reproducibility of volumetric MR imaging measurements of plexiform neurofibromas","volume":"180","author":"Poussaint","year":"2003","journal-title":"AJR Am J Roentgenol"},{"key":"10.1002\/pbc.25041-BIB0027|pbc25041-cit-0027","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1212\/01.wnl.0000179303.72345.ce","article-title":"The nature and frequency of cognitive deficits in children with neurofibromatosis type 1","volume":"65","author":"Hyman","year":"2005","journal-title":"Neurology"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.25041","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.25041","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/pbc.25041\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T07:06:59Z","timestamp":1625382419000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.25041"}},"subtitle":["Pirfenidone Phase II Trial in NF1 and PN"],"short-title":[],"issued":{"date-parts":[[2014,4,22]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"URL":"https:\/\/doi.org\/10.1002\/pbc.25041","archive":["Portico"],"relation":{},"ISSN":["1545-5009"],"issn-type":[{"value":"1545-5009","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4,22]]}}}